FDA Inspection 1298296 — Mitsubishi Tanabe Pharma America, Inc.
The FDA completed an inspection of Mitsubishi Tanabe Pharma America, Inc. on Sep 18, 2025 in Jersey City, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 18, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Jersey City, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)